One is that the development of DPP-4 inhibition is a rational drug design based in scientific studies on pathophysiology of type 2 diabetes and that the development shows that it is important to target both the impaired insulin secretion and the high glucagon
For example, if a beneficiary initiated GLP-1 therapy in September 2024 with a body mass index (BMI) of 37 and has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider should attest that the beneficiary met the BMI 35 criterion at the time therapy was initiated
Interest in these medications has recently accelerated, although access to and use of GLP-1 RA medications may be impacted by high cost, limited insurance coverage for patients without T2D, and medication shortages
Granhall, C., Rosengren, A
In a fully blinded controlled trial of 93 children (ages 712) with ADHD not taking any medication, subjects were randomized to receive a nutritional supplement providing micronutrients (13 vitamins, 17 minerals, and 4 amino acids) or placebo for 10 weeks
Endnotes Adults who say a doctor or health care provider told them they are overweight or obese in the past five years include those who may also have diabetes or heart disease